---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-012649"
form_type: "8-K"
ticker: "CVKD"
cik: "0001937993"
company_name: "Cadrenal Therapeutics, Inc."
filed_at: "2024-02-12T23:59:59+00:00"
generated_at: "2026-06-06T04:31:45.625907+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Cadrenal Therapeutics appoints Jeff Cole as COO with $405K salary and equity incentives

## Summary
- Jeff Cole appointed Chief Operating Officer, newly created role, effective Feb 8, 2024.
- Annual base salary $405K, discretionary bonus up to 40% of base, and 150,000 stock options.
- Cole brings 25+ years exp in pharma operations; previously at Espero BioPharma and Valeant.
- He will oversee manufacturing, supply chain, IP, commercialization, partnering for tecarfarin.
- Appointment comes as Cadrenal advances tecarfarin toward Phase 3 pivotal trial for anticoagulation.

## SEC filing metadata
- accession: 0001213900-24-012649
- form_type: 8-K
- ticker: CVKD
- cik: 0001937993
- company_name: Cadrenal Therapeutics, Inc.
- filed_at: 2024-02-12T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1937993/000121390024012649/0001213900-24-012649-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1937993/000121390024012649/ea193419-8k_cadrenal.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-012649
- JSON: https://secwatch.observer/filing/0001213900-24-012649.json
- Plain text: https://secwatch.observer/filing/0001213900-24-012649.txt

## Key facts
- Executive change
  Jeffrey Cole was appointed as Chief Operating Officer at Cadrenal Therapeutics, Inc..
  - Action: appointed
  - Role: Chief Operating Officer
  source text: On February 6, 2024, Cadrenal Therapeutics, Inc. (the “Company”) entered into an offer letter agreement (the “Offer Letter”) with Jeffrey Cole describing the terms of his employment as the Company’s Chief Operating Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1937993/000121390024012649/0001213900-24-012649-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.